Varex Imaging (VREX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
10 Aug, 2026Executive summary
Entered into a definitive agreement to be acquired by Teledyne Technologies, with the transaction expected to close in early 2027.
The combination aims to expand global scale, technical expertise, and resources, enhancing innovation and customer support.
Both companies will operate independently until the transaction closes, maintaining current strategies and operations.
Forward-looking statements highlight anticipated synergies, benefits for customers and employees, and integration plans.
Actual results may differ due to risks such as regulatory approvals, integration challenges, and market conditions.
Voting matters and shareholder proposals
A special meeting of stockholders will be held to vote on the adoption of the Merger Agreement.
Proxy materials will be filed with the SEC and mailed to stockholders, who are urged to review them carefully.
Board of directors and corporate governance
Directors and executive officers may be deemed participants in the proxy solicitation for the special meeting.
Information on directors, executive officers, and their security holdings is available in prior proxy statements and SEC filings.
Latest events from Varex Imaging
- Shareholders will vote on Varex's merger with Teledyne, with closing expected in early 2027.VREX
Proxy filing - Shareholders will vote on a proposed acquisition by Teledyne, expected to close in early 2027.VREX
Proxy filing - Shareholders will vote on a proposed acquisition by Teledyne, expected to close in early 2027.VREX
Proxy filing - Teledyne to acquire Varex Imaging for $18.90 per share in a $1.1B all-cash merger.VREX
Proxy filing - Quarterly revenue up 4% YoY to $211M, net income rebounded, and merger with Teledyne announced.VREX
Q3 2026 - Annual guidance, India ramp, photon counting, and AI drive growth and strategic flexibility.VREX
Jefferies Global Healthcare Conference 2026 - Q2 FY26 revenue rose 1–1.5% to $216M, with non-GAAP EPS at $0.21 and lower leverage from refinancing.VREX
Q2 2026 - Photon counting and industrial growth offset medical softness, with gradual China recovery expected.VREX
Jefferies 2024 Global Healthcare Conference - Q1 revenue up 5% to $200M, margin 35%, strong security orders, and Q2 growth outlook.VREX
Q1 2025